| __timestamp | Alnylam Pharmaceuticals, Inc. | Protagonist Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 190249000 | 7459000 |
| Thursday, January 1, 2015 | 276495000 | 11831000 |
| Friday, January 1, 2016 | 382392000 | 25705000 |
| Sunday, January 1, 2017 | 390635000 | 46181000 |
| Monday, January 1, 2018 | 505420000 | 59497000 |
| Tuesday, January 1, 2019 | 655114000 | 65003000 |
| Wednesday, January 1, 2020 | 654819000 | 74506000 |
| Friday, January 1, 2021 | 792156000 | 126006000 |
| Saturday, January 1, 2022 | 883015000 | 126215000 |
| Sunday, January 1, 2023 | 1004415000 | 120161000 |
| Monday, January 1, 2024 | 1126232000 |
Cracking the code
In the competitive world of biotechnology, innovation is the key to success. Alnylam Pharmaceuticals, Inc. and Protagonist Therapeutics, Inc. are two companies that have consistently invested in research and development (R&D) to drive their growth. Over the past decade, Alnylam has demonstrated a robust commitment to innovation, with R&D expenses growing by over 400% from 2014 to 2023. In contrast, Protagonist Therapeutics, while also increasing its R&D spending, has seen a more modest growth of around 150% during the same period.
Alnylam's investment in R&D reached its peak in 2023, with expenses surpassing $1 billion, highlighting its aggressive pursuit of groundbreaking therapies. Meanwhile, Protagonist's R&D spending, though significantly lower, reflects a steady commitment to innovation. This comparison underscores the varying strategies of these biotech firms in their quest to lead in the field of medical advancements.
Who Prioritizes Innovation? R&D Spending Compared for Pfizer Inc. and Protagonist Therapeutics, Inc.
R&D Insights: How GSK plc and Protagonist Therapeutics, Inc. Allocate Funds
Who Prioritizes Innovation? R&D Spending Compared for argenx SE and Alnylam Pharmaceuticals, Inc.
Analyzing R&D Budgets: Alnylam Pharmaceuticals, Inc. vs Genmab A/S
Analyzing R&D Budgets: Alnylam Pharmaceuticals, Inc. vs Bio-Techne Corporation
R&D Spending Showdown: Alnylam Pharmaceuticals, Inc. vs Ascendis Pharma A/S
Research and Development Investment: Dr. Reddy's Laboratories Limited vs Protagonist Therapeutics, Inc.
Amneal Pharmaceuticals, Inc. vs Protagonist Therapeutics, Inc.: Strategic Focus on R&D Spending
Who Prioritizes Innovation? R&D Spending Compared for Protagonist Therapeutics, Inc. and Iovance Biotherapeutics, Inc.
Research and Development Expenses Breakdown: Protagonist Therapeutics, Inc. vs Wave Life Sciences Ltd.
Research and Development: Comparing Key Metrics for Protagonist Therapeutics, Inc. and Travere Therapeutics, Inc.
Protagonist Therapeutics, Inc. vs BioCryst Pharmaceuticals, Inc.: Strategic Focus on R&D Spending